A Phase 3 interventional study of Meningococcal (group B) multicomponent recombinant adsorbed vaccine in Meningitis, Meningococcal, Serogroup B, sponsored by Novartis. Completed at 1 site in Poland. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-01-05.
Sponsored by Novartis · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing 4CMenB vaccine in Meningitis, Meningococcal — 1 open to participants now, 2 under way, none of them phase 3. 4CMenB vaccine · Meningitis, Meningococcal.
Among the 11 studies testing 4CMenB vaccine in Meningitis, Meningococcal, this one is the 8th largest by enrollment, is the only one that started in 2014, is one of 3 in phase 3, and was the 7th registered.
125 studies on the registry are indexed under Meningitis, Meningococcal; 10 are open to participants now.
Browse Meningitis, Meningococcal studies →1 of the 11 studies testing 4CMenB vaccine in Meningitis, Meningococcal is open now, in 1 country. Recruiting first, the newest first:
University Ghent · Sites in Belgium
Ages 18–50 · Healthy volunteers
By country, each count listing its studies:
4CMenB vaccine: first FDA approval 2014 (Trumenba). What it is approved for, and how studies give it, is on its page →
Of the 5 Meningitis, Meningococcal studies recruiting now, none set no upper age limit and 5 stop at 75 or younger; 4 take children under 18; 5 take healthy volunteers.
This study: 18 Years to 50 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 4 · Phase 3 4 · Phase 4 4
First in 2006; this study’s year is marked. 1 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 55 is below the median of 538 across 113 interventional studies indexed under Meningitis, Meningococcal.
Median enrollment 250 across the 11 interventional studies. Of the 8 that completed or were terminated, 7 (88%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 11 have an industry lead sponsor. The 6 most frequent:
Novartis is the lead sponsor of 714 studies on the registry; none are open to participants now.
32 studies in Meningitis, Meningococcal by Novartis: none open now, none under way, none of them phase 3. Of 32 finished, 28 (88%) have results posted.
Among the 32 studies in Meningitis, Meningococcal by Novartis, this one is the 29th largest by enrollment of the 30 interventional ones that give a count, is the only one that started in 2014, is one of 19 in phase 3, and was the 32nd registered.
Novartis’s Meningitis, Meningococcal studies by the year they started, since 2005.
None of the studies under way reaches primary completion within a year.
Among the 11 studies testing 4CMenB vaccine in Meningitis, Meningococcal, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 32 in Meningitis, Meningococcal:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this trial is to assess the safety of a Meningococcal Group B Vaccine and to collect blood donation. Sera panel obtained from blood donations will be used as a control to measure the immunoresponse to the Meningococcal Group B Vaccine in other studies.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects who received two doses of rMenB+OMV NZ according to a 0, 2-month schedule
Biological: Meningococcal (group B) multicomponent recombinant adsorbed vaccine
One dose (0.5 mL) vaccine administered by intramuscular (IM) injection in the deltoid area of the non-dominant arm.
Also known as: rMenB+OMV NZ
Number of Subjects Reporting Unsolicited Adverse Events (AEs).
Safety was assessed as the number of the subjects who reported unsolicited AEs following vaccination.
Time frame: From day 1 to day 7 after each vaccination (Vaccination 1: Day 1 to Day 7; Vaccination 2: Day 61 to Day 67)
Number of Adult Volunteers Whose Blood Can be Used as a Reference in Serum Bactericidal Activity (SBA) Test.
The number of identified healthy adult volunteers with pre and postvaccination blood donations were summarized to establish a control sera panel to be used as a reference in SBA test.
Time frame: Study day 1 blood sample was drawn between day -5 and day 1. Postvaccination 2 blood sample was drawn between day 23 and day 37 postvaccination 2.
Subjects will be enrolled at one site in Poland from December 2014 to February 2015.
| Milestone | rMenB+OMV NZ |
|---|---|
| Started | 55 |
| Completed | 54 |
| Not completed | 1 |
| Withdrew: Adverse event | 1 |
Safety was assessed as the number of the subjects who reported unsolicited AEs following vaccination.
| Subjects | rMenB+OMV NZ |
|---|---|
| Any Serious Adverse Events (SAEs) (vaccination 1) | 0 |
| Any Serious Adverse Events (SAEs) (vaccination 2) | 0 |
| At least possibly related SAEs (vaccination 1) | 0 |
| At least possibly related SAEs (vaccination 2) | 0 |
| AEs leading to premature withdrawal (vaccination1) | 0 |
| AEs leading to premature withdrawal (vaccination2) | 0 |
| Medically attended AEs (vaccination 1) | 0 |
| Medically attended AEs (vaccination 2) | 0 |
| AESIs (AEs of Special Interest) (vaccination 1) | 0 |
| AESIs (AEs of Special Interest) (vaccination 2) | 0 |
The number of identified healthy adult volunteers with pre and postvaccination blood donations were summarized to establish a control sera panel to be used as a reference in SBA test.
| Participants | rMenB+OMV NZ |
|---|---|
| Study Day 1 Blood Sample | 55 |
| Postvaccination 2 Blood Sample | 50 |
Collected over Safety was assessed from the day of first vaccination (Day 1) until and inclusive the day of study termination (pre-planned at Day 91).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| rMenB+OMV NZ | — | 1/55 (1.8%) | 0/55 (0%) |
| Event | rMenB+OMV NZ |
|---|---|
| MULTIPLE SCLEROSISNervous system disorders | 1/55 |
| Age, Continuous(YEARS) | rMenB+OMV NZ |
|---|---|
| Mean | 27.2 ± 6.932 |
| Sex: Female, Male(Participants) | rMenB+OMV NZ |
|---|---|
| Female | 27 |
| Male | 28 |
The record gives a start of Dec 2014, a primary completion of Apr 2015 and a completion of Apr 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2015, 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: 4CMenB vaccine